EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Longitudinal Changes in FIB-4 Score During Androgen Deprivation Therapy in Patients with Prostate Cancer

İrfan Şafak Barlas, Tuğba Barlas, Lütfi Tunç

Endocrinology Research and Practice · 04.08.2026

DOI: 10.5152/erp.2026.261001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology Research and Practice, online erschienen am 04.08.2026. Verfasst von İrfan Şafak Barlas und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Androgen deprivation therapy (ADT) is associated with adverse metabolic effects; however, its impact on noninvasive markers of liver fibrosis remains unclear. This study aimed to evaluate longitudinal changes in the FIB-4 score in patients with prostate cancer receiving luteinizing hormone– releasing hormone (LHRH) agonist therapy.

Methods

This retrospective study included 74 patients with prostate cancer treated with LHRH agonists. FIB-4 scores were assessed at baseline, 6 months, and 12 months. Longitudinal comparisons were performed among patients with complete data at all 3 time points (n = 42) using a Friedman test with Bonferroni pairwise comparisons.

Results

A total of 74 patients were included. Total prostate-specific antigen (PSA) and total testosterone levels decreased significantly after treatment (P < .001). Metabolic parameters, including HbA1c, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), remained unchanged after 6 months of ADT (P > .05). Among the 42 patients with complete follow-up, no significant change in FIB-4 score was observed at 6 months (adjusted P = .243); however, a significant increase was observed at 12 months (adjusted P = .036), with a median absolute change of 0.25 (Q1–Q3: −0.11 to 0.49; 95% CI: 0.07–0.62), indicating a time-dependent pattern.

Conclusion

FIB-4 scores remained stable during the early phase of LHRH agonist therapy but increased significantly at 12 months, indicating a delayed effect of ADT on liver fibrosis markers. These findings underscore the need for longitudinal monitoring of liver-related parameters in patients undergoing long-term ADT. Cite this article as: Barlas IS, Barlas T, Tunc L. Longitudinal changes in FIB-4 score during androgen deprivation therapy in patients with prostate cancer. Endocrinol Res Pract. . Published online August 1, 2026. doi: 10.5152/erp.2026.261001.

Zitieren

APA

Barlas, İ. Ş., Barlas, T., & Tunç, L. (2026). Longitudinal Changes in FIB-4 Score During Androgen Deprivation Therapy in Patients with Prostate Cancer. Endocrinology Research and Practice. https://doi.org/10.5152/erp.2026.261001

Vancouver

Barlas İŞ, Barlas T, Tunç L. Longitudinal Changes in FIB-4 Score During Androgen Deprivation Therapy in Patients with Prostate Cancer. Endocrinology Research and Practice. 2026. doi:10.5152/erp.2026.261001

BibTeX
@article{Barlas2026,
  author = {Barlas, İrfan Şafak and Barlas, Tuğba and Tunç, Lütfi},
  title = {Longitudinal Changes in FIB-4 Score During Androgen Deprivation Therapy in Patients with Prostate Cancer},
  journal = {Endocrinology Research and Practice},
  year = {2026},
  doi = {10.5152/erp.2026.261001}
}
Kostenlos starten →